8 years ago

Pulmocide Raises $30.4 Million in Series B to Advance Inhaled Treatments for RSV and Pulmonary Aspergillosis

  • Pulmocide, a UK-based drug discovery company developing inhaled treatments for RSV and pulmonary aspergillosis, has secured $30.4 million in Series B financing

  • The round was led by SR One and included Longwood Fund, SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc., and Touchstone Innovations plc

  • Pulmocide plans to use the funding to progress its wholly-owned assets through early clinical development, including its RSV antiviral agent PC786 and antifungal PC945

      • ProblemHealthcare

      "Respiratory syncytial virus (RSV) and pulmonary aspergillosis are serious respiratory infections that cause significant morbidity and mortality, particularly in vulnerable populations like infants and immunocompromised individuals."

      Solution

      "Pulmocide is developing novel inhaled medicines that target these infections directly at the site of disease, aiming to improve treatment outcomes and reduce the burden of these conditions."

      Covered on